A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lymphoma
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza chłoniaka T-komórkowego skóry lub chłoniaka T-komórkowego z zmianami na skórze, potwierdzona badaniem histologicznym
- •Co najmniej dwie zmiany skórne nadające się do wszzczepienia urządzenia, o średnicy co najmniej 1,5 cm
- •Wymierny obszar choroby na skórze
- •Wiek minimum 18 lat
- •Dobry ogólny stan zdrowia (ECOG ≤2)
- •Prawidłowe wyniki badań krwi - liczba neutrofili ≥500/mcL i płytek ≥50 000/mcL
- •Przerwanie poprzednich terapii przed wszzczepem (od 2 tygodni do 15 tygodni w zależności od rodzaju leczenia)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 27, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Dana Farber Cancer Institute
Boston, United States
Trial contact
Cecilia Larocca, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.